Relative Bioavailability of AR10 Compared to Reference Product
Study Details
Study Description
Brief Summary
This study evaluates the relative bioavailability of Acetylcysteine Effervescent Tablets (AR10) and Reference N-acetylcysteine. Patients will receive both products in an Open Label, Randomized, Two-Arm, Single-Dose, Two-Period, Crossover design.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
An Open Label, Randomized, Two-Arm, Single-Dose, Two-Period, Crossover Study Relative Bioavailability Study. The present study is intended to compare and evaluate the relative bioavailability of a single 11 gram dose of AR10 (acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g]), and the reference Listed Drug (acetylcysteine solution; oral 20% [200 mg/mL] of American Pharmaceutical Partners) in healthy adult, human subjects under fasting conditions. A balanced block randomization schedule will be generated before the start of dosing.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: AR10 AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g) |
Drug: AR10
effervescent tablet
Other Names:
|
| Active Comparator: acetylcysteine acetylcysteine solution; oral 20% (200 mg/mL) |
Drug: acetylcysteine
oral solution
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Comparison of Area Under the Curve (AUC) profiles of the two formulations of acetylcysteine to determine the Relative Bioavailability [10 days]
To compare AUC of a single 11 gram dose of AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g), and the Reference Listed Drug (acetylcysteine solution; oral 20% [200 mg/mL] from American Pharmaceutical Partners) in a minimum of 24 healthy adult, human subjects under fasting conditions, to establish relative bioavailability.
- Comparison of Maximum Plasma Concentration (Cmax) profiles of the two formulations of acetylcysteine to determine the Relative Bioavailability [10 days]
To compare Cmax of a single 11 gram dose of AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g), and the Reference Listed Drug (acetylcysteine solution; oral 20% [200 mg/mL] from American Pharmaceutical Partners) in a minimum of 24 healthy adult, human subjects under fasting conditions, to establish relative bioavailability.
Secondary Outcome Measures
- The safety and tolerability of AR10 and the reference product, as measured by treatment-emergent adverse events (AEs), concomitant medications, vital signs (pulse, temperature and respiratory rate), and assessment of well-being. [12 days]
To compare the safety and tolerability of AR10 and the reference product, as measured by treatment-emergent adverse events (AEs), concomitant medications, vital signs (pulse, temperature and respiratory rate), and assessment of well-being.
Other Outcome Measures
- Evaluation of subject preference between AR10 and the reference product using the adapted British Nutritional Foundation's Sensory Evaluation (2004) 5-point hedonic scale. [10 days]
Following each dose, subjects were asked to rate the taste, smell, flavor, texture, and overall preference of each product using the adapted British Nutritional Foundation's Sensory Evaluation (2004) 5-point hedonic scale, ranging from dislike very much to like very much. After the second dose was taken, subjects were also asked to choose which treatment they would prefer.
- Evaluation of healthcare provider preference between AR10 and the reference product using the adapted British Nutritional Foundation's Sensory Evaluation (2004) 5-point hedonic scale [10 days]
Healthcare providers involved in dispensing, preparing, and administering the study drug responded to the preference survey within 30 minutes of completing dosing activities in each study period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects (males or females) between 18 - 50 years of age inclusive.
-
Body weight at least 154 pounds (70 kg) and a Body Mass Index no greater than 30 kg/m2.
-
Healthy as determined by medical history, clinical examination, and laboratory examination performed within 30 days prior to admission for the first period of the study.
-
Subjects willing and able to provide a written informed consent, HIPPA and to adhere to the protocol requirements.
-
If female and of childbearing potential (defined as a pre-menopausal female who is biologically capable of becoming pregnant), the subject must agree to remain abstinent or practice a medically acceptable form of contraception from screening until the close out visit of the clinical study. Acceptable forms of contraception include intrauterine devices, implantable devices, and barrier methods. If a barrier method is chosen, a double barrier (e.g., condom plus foam) is required.
-
Negative beta human chorionic gonadotropin test, consistent with no pregnancy (females only).
-
Non-smokers
Exclusion Criteria:
-
Known hypersensitivity, allergy, idiosyncratic reaction or adverse reaction to acetylcysteine, its excipients, and other related compounds with similar chemical characteristics or any severe allergic reaction to any drug or multiple food/drug allergies.
-
History or current evidence of clinically significant medical condition including, but not limited to, hepatic, renal, cardiac, vascular, gastrointestinal, or thyroid disease, diabetes, epilepsy, respiratory or hematological disease, acute narrow angle glaucoma, or psychiatric disorder that, in the opinion of the Principal Investigator, would confound the study results or present a risk to the subject.
-
Subjects are to be without symptoms of nausea and/or vomiting. Subjects with a history of chronic nausea/vomiting are excluded. Subjects who had an acute illness/condition and have not had any nausea and/or vomiting episodes in the past two weeks may be screened provided they are medically cleared from the acute illness/condition involving nausea and/or vomiting episode(s).
-
Existence of any surgical or medical condition that in the judgment of Principal Investigator might interfere with the absorption, distribution, metabolism, or elimination of the investigational product.
-
Any clinically significant abnormality in the electrocardiogram (12 lead ECG).
-
Laboratory values that are considered clinically significant (clinical chemistry, hematology, coagulation, urinalysis, or pregnancy test) - Note: In the event of any parameter lying outside of the normal range, the sample may be repeated once. This value will be accepted if it lies within the normal range.
-
Consumption of grapefruit juice/grapefruit within 14 days prior to Period I admission.
-
Use of alcohol or caffeine containing products within 72 hours of each dose of °History or presence of alcoholism or drug abuse within 1 year of study participation.
-
Known or suspected carcinoma.
-
Presence of the disease markers of the human immunodeficiency virus (HIV) 1 or 2, and hepatitis B or C viruses.
-
Positive serum test for drug(s) of abuse testing (amphetamines, barbiturates, benzodiazepines, tetrahydrocannabinol, morphine, and cocaine, and alcohol).
-
History of intake/administration of any investigational treatment in a clinical study within the last 30 days prior to the onset of the study admission in Period I.
-
History of significant blood loss (≥ 350 mL) due to any reason, including blood donation, within the last 12 weeks prior to admission in Period I of the study.
-
Intake/administration of any enzyme-modifying drugs or drugs that might increase or decrease acetylcysteine levels within 30 days of investigational product administration, or over-the-counter (OTC) drugs including vitamins and natural supplements within 21 days of the first dose of Investigational Product administration and throughout study unless approved by the Principal Investigator or Sponsor.
-
Requirement of special diet preventing consumption of standard, healthy meals during the in-clinic portions of the study. In such cases, subject selection will be at the discretion of the Principal Investigator in discussion with Medical Monitor, if required.
-
Any subject who, in the opinion of the Principal Investigator, cannot or may not follow instructions.
-
Difficulty in swallowing a liquid solution.
-
Female subjects with a self-reported history of anemia during menstrual cycle which may coincide with any of the dosing day(s) during the study period.
-
Pregnant and lactating females.
-
Employee of the Sponsor, Clinical site, or Clinical research organization.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Arbor Pharmaceuticals, Inc.
Investigators
- Study Director: Tania D Johnson, RN, BSN, Arbor Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AR10.001